NEW YORK (GenomeWeb News) - Xenomics said today it has granted a co-exclusive license to Asuragen to use the NPM1 gene to develop diagnostic products for acute myeloid leukemia patients.
 
Under the sub-license agreement, Asuragen will have access to use the nucleophosmin gene, or NPM1, toward developing tests to diagnose, stratify, and monitor AML patients.
 
Xenomics holds exclusive rights to a recent discovery at the University of Perugia that has shown that many AML patients have mutations in that gene.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.